Results 131 to 140 of about 57,421 (320)
Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus
Aging Cell, Volume 24, Issue 8, August 2025.In cohorts of lean controls, obese participants without Type 2 Diabetes Mellitus (T2DM) and obese T2DM participants, we find that T‐cell expression of senescence biomarkers is altered only in the T2DM participants and not with obesity alone. Moreover, high T‐cell p16 expression in the T2DM participants is associated with impaired bone cortical indices.
Caroline Hoong +9 more
wiley +1 more source
Frontiers in Endocrinology, 2019 Background: Prediction of tumor consistency before surgery is of vital importance to determine individualized therapeutic schemes for patients with acromegaly.
Yanghua Fan +7 more
semanticscholar +1 more source
Leptin Level in Newly Diagnosed Iraqi Acromegaly Patients
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2018 Acromegaly is a serious endocrine disease resulting from an increase of growth hormone in the blood. Excessive growth hormone secretion may be caused by an adenoma of the pituitary.
Noor Thair Tahir
doaj +1 more source
Clinical Endocrinology, Volume 103, Issue 2, Page 201-208, August 2025.ABSTRACT Objective Detecting hypotonic urine (specific gravity < 1005 g/L) is crucial for the early identification of arginine vasopressin deficiency (AVP‐deficiency), a common complication after pituitary surgery. This study aimed to evaluate the agreement between urine specific gravity measurements taken by patients using urine test strips and those ...
Jeanne‐Marie Nollen +7 more
wiley +1 more source
How to Position Pasireotide LAR Treatment in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 2019 CONTEXT Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly.
Eva C. Coopmans +4 more
semanticscholar +1 more source
CNS Neuroscience &Therapeutics, Volume 31, Issue 8, August 2025.GH‐secreting pituitary adenomas exhibit spatial heterogeneity in hormone secretion, which may allow for hormone remission even in the presence of postoperative tumor residuals. ABSTRACT Background Growth hormone‐secreting pituitary neuroendocrine tumors (GH‐secreting PitNETs) pose significant health risks due to hormone‐related complications.
Yangyang Wang +6 more
wiley +1 more source
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
Frontiers in Endocrinology, 2018 Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. Indeed, chronic GH excess impairs insulin sensitivity, increases
F. Ferraù +4 more
semanticscholar +1 more source
Obstructive Sleep Apnea Syndrome in Acromegaly Before and After Treatment
Türk Uyku Tıbbı Dergisi, 2014 Introduction Obstructive sleep apnea syndrome (OSAS) prevalence in acromegaly patients is very common compared with general population. It is thought that OSAS in acromegaly patients evolve because of reversible and irreversible anatomical changes ...
Selda Korkmaz +5 more
doaj +1 more source
Journal of Intellectual Disability Research, Volume 69, Issue 8, Page 664-674, August 2025.ABSTRACT Background Sotos syndrome (SoS) is a rare genetic disorder characterised by physical overgrowth and by frequent intellectual disability and comorbidity with neurodevelopmental disorders. A recent study documented a specific cognitive profile of SoS.
Niccolò Butti +5 more
wiley +1 more source
Diagnosis and Treatment of Acromegaly: An Update.
Mayo Clinic proceedings, 2022 Nazanin Ershadinia, N. Tritos
semanticscholar +1 more source